Key Studies Influencing My Practice Following CROI 2018
DolPHIN-1 Interim Analysis: Dolutegravir-Based Regimen Appears Sufficient at Standard Dose for Women With HIV Starting ART in Third Trimester
ANDES: ART Initiation With DRV/RTV Plus 3TC Achieves Similar Efficacy to DRV/RTV Plus 3TC/TDF at 48 Weeks
Contemporary Management of HIV: How Aging Affects ART Management
HIV Alert: Options for Integrase Inhibitor Therapy Following Recent Drug Approvals
Clinical Care Options, LLC. All Rights Reserved.